Eli Lilly and Company (SWX:LLY)
Switzerland
· Delayed Price · Currency is CHF | Market Cap | 614.72B |
| Revenue (ttm) | 40.82B |
| Net Income (ttm) | 9.60B |
| Shares Out | n/a |
| EPS (ttm) | 10.61 |
| PE Ratio | 64.06 |
| Forward PE | n/a |
| Dividend | 4.81 (0.79%) |
| Ex-Dividend Date | Feb 14, 2025 |
| Volume | n/a |
| Average Volume | 3 |
| Open | n/a |
| Previous Close | 675.00 |
| Day's Range | n/a |
| 52-Week Range | 660.00 - 830.00 |
| Beta | 0.33 |
| RSI | 45.78 |
| Earnings Date | May 1, 2025 |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja... [Read more]
Financial Performance
In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.
Financial numbers in USD Financial StatementsNews
Novo Nordisk slides after Eli Lilly's results for oral weight loss drug—orforglipron
Novo Nordisk Shares Fall After Data From New Eli Lilly Pill
Shares fell after Eli Lilly announced results of a new pill that could rival the weight-loss potential of the Danish giant's blockbuster shots.
5 Reasons To Buy Eli Lilly
LLY, NVO and AMGN Forecast – Pharma Stocks to Open Mixed
The three pharma stocks in this analysis all look a bit mixed in the premarket, after seeing some momentum late last week. This is especially true with LLY, as you will see on the charts.
US Stocks Likely To Open Lower: 'Best And Worst Days Tend To Occur Near The Same Time,' Says Expert
U.S. stock futures fell on Monday, following a holiday-shortened week that ended with a mixed performance on Thursday. Major benchmark indices were trading lower in the premarket session. Chinese Mini...
Dow Dips Over 500 Points, Down For 3rd Straight Session As UnitedHealth Tanks: Greed Index Remains In 'Extreme Fear' Zone
The CNN Money Fear and Greed index remained in the “Extreme Fear” zone on Friday. U.S. stocks settled mostly lower on Thursday, with the Dow Jones index falling more than 500 points during the session...
Notable healthcare headlines for the week: UnitedHealth, Eli Lilly, J&J in focus
Stocks dropped this holiday-shortened week under tariff tensions and U.S. economic policies.
Eli Lilly: A New Leader In Weight Loss Drugs Is Clearly Emerging
Prediction: Eli Lilly's Newest GLP-1 Drug Will Be a Game-Changer for the Stock
Benzinga Bulls And Bears: Netflix, UnitedHealth, Eli Lilly — And Market Volatility Continues
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories. U.S. markets faced heightened volatility this week as the Trump admin...
Eli Lilly's Experimental Weight Loss Pill Succeeded in Its First Pivotal Trial. Is It Time to Buy?
The Score: UnitedHealth, Netflix, Eli Lilly and More Stocks That Defined the Week
Here are some of the major companies whose stocks moved on the week's news
The Score: UnitedHealth, Netflix, Eli Lilly and More Stocks That Defined the Week
Eli Lilly (LLY) Boosts U.S. Manufacturing with Promising Weight-Loss Pill
Eli Lilly (LLY) Boosts U.S. Manufacturing with Promising Weight-Loss Pill
Eli Lilly plans to make weight-loss pill in U.S. amid Trump’s reshoring push
Eli Lilly invests $27B in U.S. manufacturing for a weight-loss pill as demand grows.
Novo Nordisk (NVO) Downgraded Amid Rising Competition from Eli Lilly
Novo Nordisk (NVO) Downgraded Amid Rising Competition from Eli Lilly
Eli Lilly Vows to Make Weight-Loss Pill in U.S. as Trump Pushes for Domestic Manufacturing
Eli Lilly plans to make its experimental drug orforglipron in the U.S. after it secures regulatory approval, says CEO Dave Ricks.
Where Will Eli Lilly Be in 5 Years?
Eli Lilly (LLY) Leads GLP-1 Market with Oral Weight Loss Drug Breakthrough
Eli Lilly (LLY) Leads GLP-1 Market with Oral Weight Loss Drug Breakthrough
Eli Lilly (LLY) Shares Surge on Promising New Weight-Loss Pill
Eli Lilly (LLY) Shares Surge on Promising New Weight-Loss Pill
Eli Lilly’s new obesity pill lowers blood sugar and aids weight loss
Promising late-stage trial results lift US pharmaceutical group’s shares almost 15%
Daily weight-loss pill could rival Ozempic, trial shows
Eli Lilly said clinical results of its GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable drugs.
Eli Lilly jumps on GLP-1 pill trial success
CNBC's Angelica Peebles joins 'Fast Money' to talk the latest on oral GLP-1 trials.
Eli Lilly jumps on GLP-1 pill trial success
CNBC's Angelica Peebles joins 'Fast Money' to talk the latest on oral GLP-1 trials.
Eli Lilly's weight-loss pill: What it means for the sector
Eli Lilly surged during Thursday's trading session after promising test results came out of the pharmaceutical company's ongoing weight-loss pill trial. Bernstein US biopharmaceuticals senior analyst ...